Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum apical membrane antigen 1 (AMA1) is an integral membrane protein and a key molecule involved in the invasion of erythrocytes by malaria parasites. It is considered one of the leading vaccine candidates for malaria due to its essential role in parasite survival and its ability to elicit strong immune responses. AMA1 interacts with rhoptry neck protein RON2 on host cells, forming part of the moving junction complex necessary for successful erythrocyte invasion by merozoites. Disruption or inhibition of AMA1 function blocks parasite entry into red blood cells. However, high sequence polymorphism among field isolates poses challenges for broad vaccine efficacy due to strain-specific immunity.
Inhibition of erythrocyte invasion
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum Apical Membrane Antigen 1 (AMA1).